Further characterization of the role that ERG plays in PTEN-intact prostate cancers and/or in hormone-sensitive prostate cancers may reveal their interwoven molecular dependencies and the molecular mechanisms driving disease progression potentially leading to new treatment stratification schemes. Here, PTEN is linked to prostate cancer.